
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2837832/publications.pdf

Version: 2024-02-01



#	Article	IF	Citations
1	Expression of CXCR4 Predicts Poor Prognosis in Patients with Malignant Melanoma. Clinical Cancer Research, 2005, 11, 1835-1841.	7.0	260
2	Pegylated Arginine Deiminase Treatment of Patients With Unresectable Hepatocellular Carcinoma: Results From Phase I/II Studies. Journal of Clinical Oncology, 2004, 22, 1815-1822.	1.6	238
3	Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. Journal of Clinical Oncology, 2005, 23, 7660-7668.	1.6	218
4	Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma. Journal of Clinical Oncology, 2010, 28, 2220-2226.	1.6	163
5	Overexpression of Both CXC Chemokine Receptor 4 and Vascular Endothelial Growth Factor Proteins Predicts Early Distant Relapse in Stage II-III Colorectal Cancer Patients. Clinical Cancer Research, 2006, 12, 2795-2803.	7.0	158
6	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clinical Immunology, 2010, 134, 237-250.	3.2	131
7	Human Melanoma Metastases Express Functional CXCR4. Clinical Cancer Research, 2006, 12, 2427-2433.	7.0	114
8	Oxidative Stress and Mitochondrial Dysfunction across Broad-Ranging Pathologies: Toward Mitochondria-Targeted Clinical Strategies. Oxidative Medicine and Cellular Longevity, 2014, 2014, 1-27.	4.0	108
9	Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Biogerontology, 2010, 11, 401-419.	3.9	106
10	Oxidative Stress and Mitochondrial Dysfunction in Down Syndrome. Advances in Experimental Medicine and Biology, 2012, 724, 291-299.	1.6	100
11	Prognostic Value of Circulating Melanoma Cells Detected by Reverse Transcriptase–Polymerase Chain Reaction. Journal of Clinical Oncology, 2003, 21, 767-773.	1.6	91
12	Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells. Cancer Immunology, Immunotherapy, 2005, 54, 781-791.	4.2	78
13	Preclinical Development of a Novel Class of CXCR4 Antagonist Impairing Solid Tumors Growth and Metastases. PLoS ONE, 2013, 8, e74548.	2.5	76
14	Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis, 2009, 204, 586-589.	0.8	75
15	Multiple evidence for an early age pro-oxidant state in Down Syndrome patients. Biogerontology, 2006, 7, 211-220.	3.9	70
16	Regulatory T cells, interleukin (IL)-6, IL-8, Vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. BJU International, 2013, 112, 686-696.	2.5	70
17	Potential Anti-Inflammatory Effects of the Hydrophilic Fraction of Pomegranate (Punica granatum L.) Seed Oil on Breast Cancer Cell Lines. Molecules, 2014, 19, 8644-8660.	3.8	66
18	Detection of Occult Melanoma Cells in Paraffin-Embedded Histologically Negative Sentinel Lymph Nodes Using a Reverse Transcriptase Polymerase Chain Reaction Assay. Journal of Clinical Oncology, 2001, 19, 1437-1443.	1.6	63

#	Article	IF	CITATIONS
19	Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management. Biological Chemistry, 2012, 393, 11-21.	2.5	57
20	Structural and functional studies of the human selenium binding protein-1 and its involvement in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 513-522.	2.3	51
21	Sjà gren's syndrome-associated oxidative stress and mitochondrial dysfunction: Prospects for chemoprevention trials. Free Radical Research, 2013, 47, 71-73.	3.3	51
22	Serum cytokine levels in patients with hepatocellular carcinoma. European Cytokine Network, 2010, 21, 99-104.	2.0	45
23	In vivoprooxidant state in Werner syndrome (WS): Results from three WS patients and two WS heterozygotes. Free Radical Research, 2005, 39, 529-533.	3.3	44
24	Pegylated arginine deiminase lowers hepatitis C viral titers and inhibits nitric oxide synthesis. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 86-91.	2.8	43
25	Vitamin C Effect on Mitoxantrone-Induced Cytotoxicity in Human Breast Cancer Cell Lines. PLoS ONE, 2014, 9, e115287.	2.5	38
26	Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa Fetoprotein. Annals of Surgical Oncology, 1999, 6, 178-185.	1.5	37
27	CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type. Cancer Immunology, Immunotherapy, 2007, 56, 1589-1595.	4.2	36
28	Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis to cirrhosis. European Cytokine Network, 2010, 21, 251-6.	2.0	36
29	Effects of Lipoic Acid, Caffeic Acid and a Synthesized Lipoyl-Caffeic Conjugate on Human Hepatoma Cell Lines. Molecules, 2011, 16, 6365-6377.	3.8	34
30	Evaluation of Selenite Effects on Selenoproteins and Cytokinome in Human Hepatoma Cell Lines. Molecules, 2013, 18, 2549-2562.	3.8	30
31	Human Cytokinome: a new challenge for systems biology. Bioinformation, 2010, 5, 166-167.	0.5	29
32	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. European Journal of Cancer, 2007, 43, 137-143.	2.8	28
33	Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. Journal of Translational Medicine, 2010, 8, 109.	4.4	27
34	Cytokinome Profile of Patients with Type 2 Diabetes and/or Chronic Hepatitis C Infection. PLoS ONE, 2012, 7, e39486.	2.5	27
35	Evaluation of the Selenotranscriptome Expression in Two Hepatocellular Carcinoma Cell Lines. Analytical Cellular Pathology, 2015, 2015, 1-6.	1.4	27
36	Soluble interleukin-2 receptor in stage l–III melanoma. Cytokine, 2006, 33, 150-155.	3.2	24

#	Article	IF	Citations
37	From clinical description, to in vitro and animal studies, and backward to patients: Oxidative stress and mitochondrial dysfunction in Fanconi anemia. Free Radical Biology and Medicine, 2013, 58, 118-125.	2.9	24
38	Cytokinome profile evaluation in patients with hepatitis C virus infection. World Journal of Gastroenterology, 2014, 20, 9261-9.	3.3	23
39	Common structural interactions between the receptors CXCR3, CXCR4 and CXCR7 complexed with their natural ligands, CXCL11 and CXCL12, by a modeling approach. Cytokine, 2013, 64, 316-321.	3.2	22
40	Comparison of the seleno-transcriptome expression between human non-cancerous mammary epithelial cells and two human breast cancer cell lines. Oncology Letters, 2017, 13, 2411-2417.	1.8	22
41	A possible predictive marker of progression for hepatocellular carcinoma. Oncology Letters, 2011, 2, 1247-1251.	1.8	21
42	The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. PLoS ONE, 2015, 10, e0134594.	2.5	21
43	Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials. International Journal of Molecular Sciences, 2014, 15, 20169-20208.	4.1	20
44	Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer, 2006, 6, 266.	2.6	19
45	Bone marrow cell transcripts from Fanconi anaemia patients reveal <i>in vivo</i> alterations in mitochondrial, redox and <scp>DNA</scp> repair pathways. European Journal of Haematology, 2013, 91, 141-151.	2.2	19
46	Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncology Reports, 2013, 29, 2163-2168.	2.6	18
47	Structure–function relationship and evolutionary history of the human selenoprotein M (SelM) found over-expressed in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 447-456.	2.3	17
48	Immunological Phenotype Analysis of Patients with Fanconi's Anaemia and Their Family Members. Acta Haematologica, 1998, 100, 39-43.	1.4	16
49	Impaired diastolic function in $na\tilde{A}$ ve untreated human immunodeficiency virus infected patients. World Journal of Cardiology, 2010, 2, 98.	1.5	16
50	Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines. Scientific World Journal, The, 2014, 2014, 1-9.	2.1	15
51	The Nâ€terminal Region of CXCL11 as Structural Template for CXCR3 Molecular Recognition: Synthesis, Conformational Analysis, and Binding Studies. Chemical Biology and Drug Design, 2012, 80, 254-265.	3.2	14
52	Prospective clinical trials of biotherapies in solid tumors: a 5-year survey. Cancer Immunology, Immunotherapy, 2005, 54, 44-50.	4.2	12
53	A Holistic Approach to Study the Effects of Natural Antioxidants on Inflammation and Liver Cancer. Cancer Treatment and Research, 2014, 159, 311-323.	0.5	12
54	Mutation analysis of candidate genes in melanoma-prone families. Melanoma Research, 2003, 13, 571-579.	1.2	11

#	Article	IF	CITATIONS
55	Adjuvant treatment of malignant melanoma: Where are we?. Critical Reviews in Oncology/Hematology, 2006, 57, 45-52.	4.4	10
56	Intermediate dose recombinant interferon-? as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon. Cancer, 2000, 89, 1490-1494.	4.1	9
57	Peptides targeting chemokine receptor CXCR4: structural behavior and biological binding studies. Journal of Peptide Science, 2014, 20, 270-278.	1.4	8
58	Basic amino acids and dimethylarginines targeted metabolomics discriminates primary hepatocarcinoma from hepatic colorectal metastases. Metabolomics, 2014, 10, 1026-1035.	3.0	7
59	Evidence of publication bias in clinical trials of biotherapies for solid tumors. Cancer, 2005, 103, 653-653.	4.1	5
60	Dissimilar cytokine patterns in different human liver and colon cancer cell lines. Cytokine, 2013, 64, 584-589.	3.2	4
61	CD4+CD45RA+CXCR4+ lymphocytes are inversely associated with progression in stages l–III melanoma patients. Cancer Immunology, Immunotherapy, 2010, 59, 511-517.	4.2	1